Correction To: Unveiling the Next Generation of MRI Contrast Agents: Current Insights and Perspectives on Ferumoxytol-Enhanced MRI.

Guangxiang Si,Yue Du,Peng Tang,Gao Ma,Zhaochen Jia,Xiaoyue Zhou,Dan Mu,Yan Shen,Yi Lu,Yu Mao,Chuan Chen,Yan Li,Ning Gu

DOI: https://doi.org/10.1093/nsr/nwae156

IF: 20.6

2024-01-01

National Science Review

Abstract:[This corrects the article DOI: 10.1093/nsr/nwae057.].

What problem does this paper attempt to address?

Unveiling the Next Generation of MRI Contrast Agents: Current Insights and Perspectives on Ferumoxytol-Enhanced MRI

Guangxiang Si,Yue Du,Peng Tang,Gao Ma,Zhaochen Jia,Xiaoyue Zhou,Dan Mu,Yan Shen,Yi Lu,Yu Mao,Chuan Chen,Yan Li,Ning Gu

DOI: https://doi.org/10.1093/nsr/nwae057

IF: 20.6

2024-01-01

National Science Review

Abstract:Contrast-enhanced magnetic resonance imaging (CE-MRI) is a pivotal tool for global disease diagnosis and management. Since its clinical availability in 2009, the off-label use of ferumoxytol for ferumoxytol-enhanced MRI (FE-MRI) has significantly reshaped CE-MRI practices. Unlike MRI that is enhanced by gadolinium-based contrast agents, FE-MRI offers advantages such as reduced contrast agent dosage, extended imaging windows, no nephrotoxicity, higher MRI time efficiency and the capability for molecular imaging. As a leading superparamagnetic iron oxide contrast agent, ferumoxytol is heralded as the next generation of contrast agents. This review delineates the pivotal clinical applications and inherent technical superiority of FE-MRI, providing an avant-garde medical-engineering interdisciplinary lens, thus bridging the gap between clinical demands and engineering innovations. Concurrently, we spotlight the emerging imaging themes and new technical breakthroughs. Lastly, we share our own insights on the potential trajectory of FE-MRI, shedding light on its future within the medical imaging realm. This review explores how ferumoxytol-enhanced MRI revolutionizes diagnostics with safer contrast options, offering a glimpse into advanced imaging techniques and promising new directions in medical research.
Unveiling the Next Generation of MRI Contrast Agents: Current Insights and Perspectives on Ferumoxytol-Enhanced MRI.

Guangxiang Si,Yue Du,Peng Tang,Gao Ma,Zhaochen Jia,Xiaoyue Zhou,Dan Mu,Yan Shen,Yi Lu,Yu Mao,Chuan Chen,Yan Li,Ning Gu

DOI: https://doi.org/10.1093/nsr/nwae057

IF: 20.6

2024-01-01

National Science Review

Abstract:Contrast-enhanced magnetic resonance imaging (CE-MRI) is a pivotal tool for global disease diagnosis and management. Since its clinical availability in 2009, the off-label use of ferumoxytol for ferumoxytol-enhanced MRI (FE-MRI) has significantly reshaped CE-MRI practices. Unlike MRI that is enhanced by gadolinium-based contrast agents, FE-MRI offers advantages such as reduced contrast agent dosage, extended imaging windows, no nephrotoxicity, higher MRI time efficiency and the capability for molecular imaging. As a leading superparamagnetic iron oxide contrast agent, ferumoxytol is heralded as the next generation of contrast agents. This review delineates the pivotal clinical applications and inherent technical superiority of FE-MRI, providing an avant-garde medical-engineering interdisciplinary lens, thus bridging the gap between clinical demands and engineering innovations. Concurrently, we spotlight the emerging imaging themes and new technical breakthroughs. Lastly, we share our own insights on the potential trajectory of FE-MRI, shedding light on its future within the medical imaging realm.
Correction: Corrigendum: Quantitative real-time imaging of glutathione

Xiqian Jiang,Jianwei Chen,Aleksandar Bajić,Chengwei Zhang,Xianzhou Song,Shaina L. Carroll,Zhao-Lin Cai,Meiling Tang,Mingshan Xue,Ninghui Cheng,Christian P. Schaaf,Feng Li,Kevin R. MacKenzie,Allan Chris M. Ferreon,Fan Xia,Meng C. Wang,Mirjana Maletić-Savatić,Jin Wang

DOI: https://doi.org/10.1038/ncomms16163

IF: 16.6

2017-01-01

Nature Communications

Abstract:Nature Communications 8: Article number: 16087 (2017); Published 13 July 2017; Updated 3 October 2017. Previous work by Cho and Choi describing the development of a cyanoacrylamide-based fluorescence sensor for reversible detection of thiols in homogenous solutions was inadvertently omitted from thereference list of this Article.
Research Progress of Magnetic Resonance Imaging Contrast Agents

Xiao Yan,Wu Yi-Jie,Zhang Wen-Jun,Li Xiao-Jing,Pei Feng-Kui

DOI: https://doi.org/10.1016/s1872-2040(10)60438-0

IF: 1.193

2011-01-01

Chinese Journal of Analytical Chemistry

Abstract:Magnetic resonance imaging (MRI) is one of the most useful diagnostic techniques in clinical medicine and more than 30% of all MRI examinations are accompanied by administration of a contrast agent which has become a class of pharmaceuticals. The principles, characterization and classification and recent developments of MRI contrast agents are presented in this review. The primary focus of such research is to study the MRI contrast agents with organ-selectivity, high relaxivity and safety.
Erratum: "New contrast agents for photoacoustic imaging and theranostics: Recent 5-year overview on phthalocyanine/naphthalocyanine-based nanoparticles" [APL Bioeng. 5, 031510 (2021)]

Eun-Yeong Park,Donghyeon Oh,Sinyoung Park,Wangyu Kim,Chulhong Kim

DOI: https://doi.org/10.1063/5.0074334

2021-10-20

Abstract:[This corrects the article DOI: 10.1063/5.0047660.].
Preparation of AS1411 Aptamer Modified Mn-MoS2 QDs for Targeted MR Imaging and Fluorescence Labelling of Renal Cell Carcinoma [Corrigendum]

Shaohui Zheng,Min Zhang,Hongyan Bai,Meijuan He,Lina Dong,Lulu Cai,Mingming Zhao,Qi Wang,Kai Xu,Jingjing Li

DOI: https://doi.org/10.2147/ijn.s405918

IF: 7.033

2023-01-01

International Journal of Nanomedicine

Abstract:[This corrects the article DOI: 10.2147/IJN.S215883.].

pharmacology & pharmacy,nanoscience & nanotechnology
Correction: Gadolinium-doped carbon dots with high-performance in dual-modal molecular imaging

Le Wang,Wenjie Zhou,Dan Yang,Zhe Hu,Shiliang Mei,Jun Yuan,Wanlu Zhang,Hui Li,Hong Fan,Fengxian Xie,Ruiqian Guo

DOI: https://doi.org/10.1039/d1ay90078a

IF: 3.1

2021-01-01

Analytical Methods

Abstract:Correction for ‘Gadolinium-doped carbon dots with high-performance in dual-modal molecular imaging’ by Le Wang et al. , Anal. Methods , 2021, 13 , 2442–2449, DOI: 10.1039/d1ay00270h.

spectroscopy,chemistry, analytical,food science & technology
Correction: A mesoporous polydopamine nanoparticle enables highly efficient manganese encapsulation for enhanced MRI-guided photothermal therapy

Yan Wu,Yu Huang,Chunlai Tu,Fengren Wu,Gangsheng Tong,Yue Su,Li Xu,Xiaoqin Zhang,Shuqiang Xiong,Xinyuan Zhu

DOI: https://doi.org/10.1039/d1nr90265b

IF: 6.7

2022-01-01

Nanoscale

Abstract:Correction for ‘A mesoporous polydopamine nanoparticle enables highly efficient manganese encapsulation for enhanced MRI-guided photothermal therapy’ by Yan Wu et al. , Nanoscale , 2021, 13 , 6439–6446, DOI: D1NR00957E.

materials science, multidisciplinary,physics, applied,nanoscience & nanotechnology,chemistry
Correction: Malachite green: a long-buried water-soluble AIEgen with near-infrared fluorescence for living cell nucleus staining

Yuan Luo,Lihua Zhou,Lili Du,Yangzi Xie,Xiang-Yang Lou,Lintao Cai,Ben Zhong Tang,Ping Gong,Pengfei Zhang

DOI: https://doi.org/10.1039/d4cc90349h

2024-10-24

Abstract:Correction for 'Malachite green: a long-buried water-soluble AIEgen with near-infrared fluorescence for living cell nucleus staining' by Yuan Luo et al., Chem. Commun., 2024, 60, 1452-1455, https://doi.org/10.1039/D3CC05535C.
Correction: FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

Pingping Liang,Jinjun Shao,Qianyun Tang,Weili Si,Qiang Wang,Qi Zhang,Xiaochen Dong

DOI: https://doi.org/10.1039/d3ra90050a

IF: 4.036

2023-01-01

RSC Advances

Abstract:Correction for ‘FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy’ by Pingping Liang et al. , RSC Adv. , 2017, 7 , 37369–37373, https://doi.org/10.1039/C7RA06551E.

chemistry, multidisciplinary
Author Correction: Radiology: Handy magnetic resonance coils

Elmar Laistler,Ewald Moser

DOI: https://doi.org/10.1038/s41551-018-0295-x

Abstract:In the version of this News and Views article originally published, the author name, title and year were incorrect in ref. 14 and should have read "Yang, X. et al. Coaxial cable magnetic resonance image (MRI) coil. US patent US9678180B2 (2017)." This error has now been corrected.
Erratum to “Near-infrared responsive 5-fluorouracil and indocyanine green loaded MPEG-PCL nanoparticle integrated with dissolvable microneedle for skin cancer therapy” [Bioact. Mater. 5 (2020) 542–552]

Ying Hao,YuWen Chen,XinLong He,Fan Yang,RuXia Han,ChengLi Yang,Wei Li,ZhiYong Qian

DOI: https://doi.org/10.1016/j.bioactmat.2020.05.005

IF: 18.9

2021-01-01

Bioactive Materials

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2020.04.002.].

engineering, biomedical,materials science, biomaterials
Solid-state Synthesis of Monocrystalline Iron Oxide Nanoparticle Based Ferrofluid Suitable for Magnetic Resonance Imaging Contrast Application

Jun Lu,Shihe Yang,Ka Ming Ng,Chia‐Hao Su,Chen-Sheng Yeh,Yu‐Hsueh Wu,Dar-Bin Shieh

DOI: https://doi.org/10.1088/0957-4484/18/28/289001

IF: 3.5

2007-01-01

Nanotechnology

Abstract:The authors regret that there was an error in the final published version of this article. There is a misprint in the concentration of maghemite nanoparticles colloid used in the in vitro biocompatibility test. In line 6 of the figure caption for Figure 7 of page 5818, `10 mg ml-1 of nanoparticles, should be corrected to `10-1 mg Fe ml-1 of nanoparticles,. The conclusions of the paper do not change.
Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy

Fuqiang Xing,Nana Ai,Shigao Huang,Cheng Jiang,Muhammad Jameel Mughal,Wei Ge,Guanyu Wang,Chu-Xia Deng

DOI: https://doi.org/10.3389/fbioe.2022.1039177

IF: 5.7

2022-09-26

Frontiers in Bioengineering and Biotechnology

Abstract:[This corrects the article DOI: 10.3389/fbioe.2022.839078.].

multidisciplinary sciences
MRI Detection and Therapeutic Enhancement of Ferumoxytol Internalization in Glioblastoma Cells

Michael S. Petronek,Nahom Teferi,Chu-Yu Lee,Vincent A. Magnotta,Bryan G. Allen

DOI: https://doi.org/10.3390/nano14020189

IF: 5.3

2024-01-13

Nanomaterials

Abstract:Recently, the FDA-approved iron oxide nanoparticle, ferumoxytol, has been found to enhance the efficacy of pharmacological ascorbate (AscH−) in treating glioblastoma, as AscH− reduces the Fe3+ sites in the nanoparticle core. Given the iron oxidation state specificity of T2* relaxation mapping, this study aims to investigate the ability of T2* relaxation to monitor the reduction of ferumoxytol by AscH− with respect to its in vitro therapeutic enhancement. This study employed an in vitro glioblastoma MRI model system to investigate the chemical interaction of ferumoxytol with T2* mapping. Lipofectamine was utilized to facilitate ferumoxytol internalization and assess intracellular versus extracellular chemistry. In vitro T2* mapping successfully detected an AscH−-mediated reduction of ferumoxytol (25.6 ms versus 2.8 ms for FMX alone). The T2* relaxation technique identified the release of Fe2+ from ferumoxytol by AscH− in glioblastoma cells. However, the high iron content of ferumoxytol limited T2* ability to differentiate between the external and internal reduction of ferumoxytol by AscH− (ΔT2* = +839% for external FMX and +1112% for internal FMX reduction). Notably, the internalization of ferumoxytol significantly enhances its ability to promote AscH− toxicity (dose enhancement ratio for extracellular FMX = 1.16 versus 1.54 for intracellular FMX). These data provide valuable insights into the MR-based nanotheranostic application of ferumoxytol and AscH− therapy for glioblastoma management. Future developmental efforts, such as FMX surface modifications, may be warranted to enhance this approach further.

materials science, multidisciplinary,physics, applied,nanoscience & nanotechnology,chemistry
Recent development in targeted MRI negative contrast based on ultra-small superparamagnetic iron oxide particles

Lijiang HU,Wenxian GUAN

DOI: https://doi.org/10.3969/j.issn.1000-8179.2013.07.014

2013-01-01

Chinese Journal of Clinical Oncology

Abstract:Ultra-small superparamagnetic iron oxide(USPIO) particles have been clinically applied in MRI negative contrast in recent years because of the particles high spatial resolution and low toxicity.With the rapid development of molecular imaging and polymer technology,numerous kinds of tumor-targeted MRI negative contrast have been investigated comprehensively.Combining USPIO with different tumor-targeting carriers in the early diagnosis of cancer,assessing the therapeutic effect,and tracing cancer stem cells have great potential and advantages compared with traditional gadolinium chelates MRI contrast.
Correction: Indocyanine-green-loaded microbubbles for localization of sentinel lymph node using near-infrared fluorescence/ultrasound imaging: a feasibility study

Long Wang,Yihe Hu,Qinghai Peng,Jiawei Zhou,Qichang Zhou,Senbo An,Chengcheng Niu

DOI: https://doi.org/10.1039/d3ra90075d

IF: 4.036

2023-01-01

RSC Advances

Abstract:Correction for ‘Indocyanine-green-loaded microbubbles for localization of sentinel lymph node using near-infrared fluorescence/ultrasound imaging: a feasibility study’ by Long Wang et al. , RSC Adv. , 2016, 6 , 50513–50520, https://doi.org/10.1039/C5RA26814A.

chemistry, multidisciplinary
Correction to: Gold and Hairpin DNA Functionalization of Upconversion Nanocrystals for Imaging and In Vivo Drug Delivery (Advanced Materials, (2017), 29, 18, (1700244), 10.1002/adma.201700244)

Sanyang Han,Animesh Samanta,Xiaoji Xie,Ling Huang,Juanjuan Peng,Sungjin Park,Daniel Boon Loong Teh,Yongdoo Choi,Young-Tae Chang,Angelo H. All,Yanmei Yang,Bengang Xing,Xiaogang Liu

DOI: https://doi.org/10.1002/adma.201704811

IF: 29.4

2017-01-01

Advanced Materials

Abstract:Adv. Mater. 2017, 29, 1700244 In Figure 2d of the originally published article, the (+) and (−) labels denoting the presence or absence of linker DNA were placed over the wrong samples. The figure is corrected here:
Correction: Engineering Cu 2− x S-conjugated upconverting nanocomposites for NIR-II light-induced enhanced chemodynamic/photothermal therapy of cancer

Kaimin Du,Shuang Zhao,Jing Feng,Xuan Gao,Kai Liu,Xiaozhen Wang,Manli Zhang,Yao Li,Yu Lu,Hongjie Zhang

DOI: https://doi.org/10.1039/d1tb90070f

IF: 7.571

2021-01-01

Journal of Materials Chemistry B

Abstract:Correction for ‘Engineering Cu 2− x S-conjugated upconverting nanocomposites for NIR-II light-induced enhanced chemodynamic/photothermal therapy of cancer’ by Kaimin Du et al. , J. Mater. Chem. B , 2021, DOI: 10.1039/d1tb00337b.

materials science, biomaterials
Corrigendum to “Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice” [Bioactive materials 6 (2021) 529–542]

Yang Han,Chunhong Gao,Hao Wang,Jiejie Sun,Meng Liang,Ye Feng,Qianqian Liu,Shiyao Fu,Lin Cui,Chunsheng Gao,Yi Li,Yang Yang,Baoshan Sun

DOI: https://doi.org/10.1016/j.bioactmat.2021.06.002

IF: 18.9

2022-01-01

Bioactive Materials

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2020.08.017.].

engineering, biomedical,materials science, biomaterials

Correction To: Unveiling the Next Generation of MRI Contrast Agents: Current Insights and Perspectives on Ferumoxytol-Enhanced MRI.

Unveiling the Next Generation of MRI Contrast Agents: Current Insights and Perspectives on Ferumoxytol-Enhanced MRI

Unveiling the Next Generation of MRI Contrast Agents: Current Insights and Perspectives on Ferumoxytol-Enhanced MRI.

Correction: Corrigendum: Quantitative real-time imaging of glutathione

Research Progress of Magnetic Resonance Imaging Contrast Agents

Erratum: "New contrast agents for photoacoustic imaging and theranostics: Recent 5-year overview on phthalocyanine/naphthalocyanine-based nanoparticles" [APL Bioeng. 5, 031510 (2021)]

Preparation of AS1411 Aptamer Modified Mn-MoS2 QDs for Targeted MR Imaging and Fluorescence Labelling of Renal Cell Carcinoma [Corrigendum]

Correction: Gadolinium-doped carbon dots with high-performance in dual-modal molecular imaging

Correction: A mesoporous polydopamine nanoparticle enables highly efficient manganese encapsulation for enhanced MRI-guided photothermal therapy

Correction: Malachite green: a long-buried water-soluble AIEgen with near-infrared fluorescence for living cell nucleus staining

Correction: FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

Author Correction: Radiology: Handy magnetic resonance coils

Erratum to “Near-infrared responsive 5-fluorouracil and indocyanine green loaded MPEG-PCL nanoparticle integrated with dissolvable microneedle for skin cancer therapy” [Bioact. Mater. 5 (2020) 542–552]

Solid-state Synthesis of Monocrystalline Iron Oxide Nanoparticle Based Ferrofluid Suitable for Magnetic Resonance Imaging Contrast Application

Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy

MRI Detection and Therapeutic Enhancement of Ferumoxytol Internalization in Glioblastoma Cells

Recent development in targeted MRI negative contrast based on ultra-small superparamagnetic iron oxide particles

Correction: Indocyanine-green-loaded microbubbles for localization of sentinel lymph node using near-infrared fluorescence/ultrasound imaging: a feasibility study

Correction to: Gold and Hairpin DNA Functionalization of Upconversion Nanocrystals for Imaging and In Vivo Drug Delivery (Advanced Materials, (2017), 29, 18, (1700244), 10.1002/adma.201700244)

Correction: Engineering Cu 2− x S-conjugated upconverting nanocomposites for NIR-II light-induced enhanced chemodynamic/photothermal therapy of cancer

Corrigendum to “Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice” [Bioactive materials 6 (2021) 529–542]